JPMorgan Chase & Co. now owns 2,855,747 shares of the company’s stock worth $61,341,000 after purchasing an additional 2,823,144 shares during the period. Balyasny Asset Management L.P. acquired a new position in shares of Immunome during the fourth quarter worth $30,710,000. Insiders Place Their BetsIn other Immunome news, CFO Max Rosett sold 60,000 shares of Immunome stock in a transaction that occurred on Monday, June 15th. Immunome Trading Up 1.1%Shares of Immunome stock opened at $23.01 on Tuesday. Immunome Company Profile(Free Report)Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases.